Predictors of disease progression in HIV infection: a review
Top Cited Papers
Open Access
- 1 January 2007
- journal article
- review article
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 4 (1) , 1-14
- https://doi.org/10.1186/1742-6405-4-11
Abstract
During the extended clinically latent period associated with Human Immunodeficiency Virus (HIV) infection the virus itself is far from latent. This phase of infection generally comes to an end with the development of symptomatic illness. Understanding the factors affecting disease progression can aid treatment commencement and therapeutic monitoring decisions. An example of this is the clear utility of CD4+ T-cell count and HIV-RNA for disease stage and progression assessment. Elements of the immune response such as the diversity of HIV-specific cytotoxic lymphocyte responses and cell-surface CD38 expression correlate significantly with the control of viral replication. However, the relationship between soluble markers of immune activation and disease progression remains inconclusive. In patients on treatment, sustained virological rebound to >10 000 copies/mL is associated with poor clinical outcome. However, the same is not true of transient elevations of HIV RNA (blips). Another virological factor, drug resistance, is becoming a growing problem around the globe and monitoring must play a part in the surveillance and control of the epidemic worldwide. The links between chemokine receptor tropism and rate of disease progression remain uncertain and the clinical utility of monitoring viral strain is yet to be determined. The large number of confounding factors has made investigation of the roles of race and viral subtype difficult, and further research is needed to elucidate their significance. Host factors such as age, HLA and CYP polymorphisms and psychosocial factors remain important, though often unalterable, predictors of disease progression. Although gender and mode of transmission have a lesser role in disease progression, they may impact other markers such as viral load. Finally, readily measurable markers of disease such as total lymphocyte count, haemoglobin, body mass index and delayed type hypersensitivity may come into favour as ART becomes increasingly available in resource-limited parts of the world. The influence of these, and other factors, on the clinical progression of HIV infection are reviewed in detail, both preceding and following treatment initiation.Keywords
This publication has 107 references indexed in Scilit:
- Analysis of Genetic Polymorphisms in CCR5, CCR2, Stromal Cell–Derived Factor–1, RANTES, and Dendritic Cell–Specific Intercellular Adhesion Molecule–3–Grabbing Nonintegrin in Seronegative Individuals Repeatedly Exposed to HIV‐1The Journal of Infectious Diseases, 2004
- Where Does HIV Live?New England Journal of Medicine, 2004
- Determinants of survival following HIV-1 seroconversion after the introduction of HAARTThe Lancet, 2003
- Do HIV Type 1 RNA Levels Provide Additional Prognostic Value to CD4+T Lymphocyte Counts in Patients with Advanced HIV Type 1 Infection?AIDS Research and Human Retroviruses, 2001
- Prognostic Value of Cross-sectional Anthropometric Indices on Short-term Risk of Mortality in Human Immunodeficiency Virus-infected Adults in Abidjan, Cote d'IvoireAmerican Journal of Epidemiology, 2001
- Survival and progression of HIV disease in women attending GUM/HIV clinics in Britain and Ireland. Study Group for the MRC Collaborative Study of HIV Infection in WomenSexually Transmitted Infections, 1999
- Serum HIV–1 RNA Levels Compared to Soluble Markers of Immune Activation to Predict Disease Progression in HIV–1–Infected IndividualsInternational Archives of Allergy and Immunology, 1998
- Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNAScience, 1998
- Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia populationThe Lancet, 1996
- The Prognostic Value of Cellular and Serologic Markers in Infection with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1990